Video Tag: Calibr-Skaggs

My life and my science | Behind the Bench with Graduate Student Leigh Sewall

Graduate student Leigh Sewall discusses her journey to Scripps Research, her experience in the Skaggs grad program and what it means to be a woman in STEM. Leigh is a recipient of the David C. Fairchild Endowed Fellowship in the Skaggs Graduate School of Chemical and Biological Sciences.

A new metastatic breast cancer trial with a “switchable” CAR-T therapy

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options. This is the first study of the sCAR-T platform in solid tumors. CAR-T therapy has been transformative for patients with hematological malignancies who failed numerous prior treatments. However, conventional CAR-T therapies have not yet been as successful at treating patients with solid tumors. This challenge is what Calibr-Skaggs’ switchable CAR-T cell therapy platform was designed to address.

A new vision for science

Scripps Research is pioneering a new model for nonprofit research institutes to address the significant health challenges facing humanity in the 21st century, from pandemic threats to the aging of the global population. Founded 100 years ago, Scripps Research is renowned in the life sciences and chemistry for scientific excellence and for training the scientific leaders of tomorrow. Building on this solid foundation, we've established a unique model that seamlessly combines world-class fundamental and translational research to accelerate the development of innovative, new medicines. We believe this model best captures the impact of groundbreaking discoveries for the benefit of human health. Moreover, revenues generated from these new medicines are reinvested into research, creating a self-renewing funding source and business model that amplifies investments in science and their ultimate impact on the public.

Combating microbial threats: A century of science changing life

Every day, scientists at Scripps Research are discovering and developing new treatments to combat today’s infectious disease threats—and tomorrow’s. Many of these researchers played a significant role in the COVID-19 pandemic, including identifying new antibody treatments and uncovering the virus’s structure. Meanwhile, they're also applying these key learnings to better prepare the global population for whichever microbial threat emerges next.